Effect of Intravenous FX06 as an Adjunct to Primary Percutaneous Coronary Intervention for Acute ST-Segment Elevation Myocardial Infarction-Reference-Cited by-同舟云学术

Effect of Intravenous FX06 as an Adjunct to Primary Percutaneous Coronary Intervention for Acute ST-Segment Elevation Myocardial Infarction

Published:2009-02 Issue:8 Volume:53 Page:720-729
ISSN:0735-1097
Container-title:Journal of the American College of Cardiology
language:en
Short-container-title:Journal of the American College of Cardiology

Author:

Atar Dan,Petzelbauer Peter,Schwitter Jürg,Huber Kurt,Rensing Benno,Kasprzak Jaroslaw D.,Butter Christian,Grip Lars,Hansen Peter R.,Süselbeck Tim,Clemmensen Peter M.,Marin-Galiano Marcos,Geudelin Bernard,Buser Peter T.

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference45 articles.

1. Guidelines for percutaneous coronary interventions;Silber;Eur Heart J,2005

2. Myocardial reperfusion injury;Yellon;N Engl J Med,2007

3. Molecular and cellular mechanisms of myocardial stunning;Bolli;Physiol Rev,1999

4. Mitochondrial permeability transition pore opening during myocardial reperfusion—a target for cardioprotection;Halestrap;Cardiovasc Res,2004

5. Reperfusion injury in humans: a review of clinical trials on reperfusion injury inhibitory strategies;Dirksen;Cardiovasc Res,2007

Cited by 136 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unlocking endothelial barrier restoration: FX06 in systemic capillary leak syndrome and beyond;Biomedicine & Pharmacotherapy;2024-02

2. FX06 to rescue SARS-CoV-2-induced acute respiratory distress syndrome: a randomized clinical trial;Critical Care;2023-08-29

3. Microvascular Leakage as Therapeutic Target for Ischemia and Reperfusion Injury;Cells;2023-05-09

4. Effects of Nicorandil Administration on Infarct Size in Patients With ST‐Segment–Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: The CHANGE Trial;Journal of the American Heart Association;2022-09-20

5. Potential of FX06 to prevent disease progression in hospitalized non-intubated COVID-19 patients — the randomized, EU-wide, placebo-controlled, phase II study design of IXION;Trials;2022-08-19